Natera, a global leader in cell-free DNA and precision medicine, reported significant revenue growth in Q4 2025 and the full year 2025.
Total revenues surged by 39% in Q4 2025 and 35% for the full year 2025 compared to the previous year.
The company processed a record number of tests, demonstrating strong demand for its services.
Revenue Growth
Total revenues increased by 39% in Q4 2025 and 35% for full year 2025, exceeding financial outlook.
Test Processing
Record number of tests processed in Q4 2025, showing growing demand for Natera's services.
Oncology Tests
Significant growth in oncology tests with a 55% increase in Q4 2025.
Cash Inflows
Achieved cash inflows of $30 million in Q4 2025 and over $100 million for the full year 2025.
Business Outlook
CEO expects strong momentum to continue in 2026 based on Q4 performance.
- Natera experienced exceptional revenue growth in 2025, surpassing expectations and demonstrating market strength.
- The increase in test processing indicates a growing demand for Natera's services, particularly in oncology diagnostics.
- The strong cash inflows in Q4 2025 and 2025 suggest financial stability and potential for future investments.
- CEO's positive outlook for 2026 reflects confidence in sustained growth and market positioning.
Natera's outstanding financial performance in Q4 2025 and the full year 2025 showcases its strong position in the precision medicine market. The record revenue growth, test processing numbers, and cash inflows highlight the company's success and potential for continued expansion in 2026.